Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 116.737 |
| 2025-03 | 134.582 |
| 2025-04 | 115.636 |
| Source | Traffic Share |
|---|---|
| search | 58.86% |
| direct | 30.95% |
| referrals | 7.51% |
| social | 1.64% |
| paid referrals | 0.90% |
| 0.11% |
| Region | Percentage |
|---|---|
| United States | 46.61% |
| India | 8.09% |
| United Kingdom | 4.39% |
| Canada | 2.69% |
| VN | 2.18% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| targeted oncology | 90 | 900 | $2.84 |
| targeted oncology, vipor | 0 | 0 | $0.00 |
| “keytruda” or “pembrolizumab” or “lynparza” or “olaparib” or “lenvima” or “lenvatinib” or "welireg" | 68 | 680 | $0.00 |
| lori wirthy | 0 | 0 | $0.00 |
| amivantamab-induced scalp and facial necrosis | 3 | 30 | $0.00 |